Curevac Nv Stock Beta
| CVAC Stock | USD 2.87 0.13 4.74% |
CureVac NV fundamentals help investors to digest information that contributes to CureVac NV's financial success or failures. It also enables traders to predict the movement of CureVac Stock. The fundamental analysis module provides a way to measure CureVac NV's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CureVac NV stock.
CureVac | Beta |
CureVac NV Company Beta Analysis
CureVac NV's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current CureVac NV Beta | 2.61 |
Most of CureVac NV's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CureVac NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CureVac Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for CureVac NV is extremely important. It helps to project a fair market value of CureVac Stock properly, considering its historical fundamentals such as Beta. Since CureVac NV's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CureVac NV's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CureVac NV's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, CureVac NV has a Beta of 2.611. This is 203.6% higher than that of the Biotechnology sector and 87.84% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
CureVac Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CureVac NV's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CureVac NV could also be used in its relative valuation, which is a method of valuing CureVac NV by comparing valuation metrics of similar companies.CureVac NV is currently under evaluation in beta category among its peers.
CureVac NV Current Valuation Drivers
We derive many important indicators used in calculating different scores of CureVac NV from analyzing CureVac NV's financial statements. These drivers represent accounts that assess CureVac NV's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CureVac NV's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 9.3B | 8.8B | 5.6B | 1.1B | 839.8M | 797.8M | |
| Enterprise Value | 9.4B | 7.5B | 4.8B | 611.0M | 479.1M | 455.2M |
CureVac NV ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CureVac NV's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CureVac NV's managers, analysts, and investors.Environmental | Governance | Social |
CureVac NV Institutional Holders
Institutional Holdings refers to the ownership stake in CureVac NV that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CureVac NV's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CureVac NV's value.| Shares | Deutsche Bank Ag | 2024-06-30 | 151 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 145.7 K | Freestone Capital Holdings, Llc | 2024-09-30 | 144.1 K | Amundi | 2024-09-30 | 122.4 K | Legal & General Group Plc | 2024-09-30 | 119 K | Boothbay Fund Management, Llc | 2024-09-30 | 113.2 K | Norges Bank | 2024-06-30 | 110.9 K | Pictet Asset Manangement Sa | 2024-09-30 | 95.4 K | Dekabank Deutsche Girozentrale | 2024-06-30 | 85.6 K | Millennium Management Llc | 2024-09-30 | 2.4 M | Blackrock Inc | 2024-06-30 | 2.3 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CureVac NV will likely underperform.
CureVac Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (4.94) % | ||||
| Current Valuation | 100.18 M | ||||
| Shares Outstanding | 224.34 M | ||||
| Shares Owned By Insiders | 45.26 % | ||||
| Shares Owned By Institutions | 18.86 % | ||||
| Number Of Shares Shorted | 4.41 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 9.78 X | ||||
| Revenue | 53.76 M | ||||
| Gross Profit | (91.55 M) | ||||
| EBITDA | (234.09 M) | ||||
| Net Income | (260.17 M) | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 41.82 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.61 X | ||||
| Book Value Per Share | 1.68 X | ||||
| Cash Flow From Operations | (267.89 M) | ||||
| Short Ratio | 9.01 X | ||||
| Earnings Per Share | 0.50 X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 6.89 | ||||
| Number Of Employees | 999 | ||||
| Beta | 2.61 | ||||
| Market Capitalization | 643.85 M | ||||
| Total Asset | 788.25 M | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 291.99 M | ||||
| Net Asset | 788.25 M |
About CureVac NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CureVac NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CureVac NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CureVac NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out CureVac NV Piotroski F Score and CureVac NV Altman Z Score analysis. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.5 | Revenue Per Share 0.294 | Quarterly Revenue Growth 0.905 | Return On Assets (0.25) | Return On Equity (0.54) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.